Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus paclitaxel and cisplatin vs paclitaxel and cisplatin in advanced esophageal squamous cell carcinoma
CTR20181718Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui Therapeutics. Started Sep 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20181718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181718.